MAC-1: A Potential Drug Target for Various Diseases (P16092)

Target Name: Integrin alphaMbeta2 (MAC-1) Receptor

NCBI ID: P16092

Integrin alphaMbeta2 (MAC-1) Receptor

Other Name(s): None

MAC-1: A Potential Drug Target for Various Diseases

Integrin alpha-Mbeta2 (MAC-1) receptor, also known as ITGB3, is a protein that is expressed in various tissues throughout the body, including the skin, hair, nails, and bones. It is a member of the integrin family, which is a group of transmembrane proteins that play a critical role in cell-cell and cell-extracellular matrix interactions. One of the functions of the MAC-1 receptor is to regulate the movement of cells, including the migration and invasion of cancer cells.

Recent studies have identified MAC-1 as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The MAC-1 receptor has been shown to play a role in the development and progression of various diseases, including cancer, and has been identified as a potential therapeutic target for these diseases.

One of the reasons for the potential of MAC-1 as a drug target is its involvement in the regulation of cell migration and invasion. MAC-1 is known to be involved in the formation of tight junctions, which are a type of cell-cell adhesion that helps to maintain tissue structure and prevent excessive fluid and tissue loss. In addition, MAC-1 is involved in the regulation of cell-extracellular matrix (ECM) interactions, which are critical for the regulation of cell position and movement.

The potential benefits of targeting MAC-1 with drugs or other therapeutic agents are significant. If successful, targeting MAC-1 with drugs could potentially lead to the development of new treatments for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, by inhibiting the activity of MAC-1, researchers could potentially slow down or stop the progression of cancer cells. In addition, targeting MAC-1 with drugs could potentially reduce the formation of new blood vessels that contribute to the development of neurodegenerative diseases.

Another promising aspect of MAC-1 as a drug target is its involvement in the regulation of inflammation. MAC-1 has been shown to be involved in the regulation of immune cell function and has been implicated in the development of various inflammatory diseases, including cancer. By targeting MAC-1 with drugs, researchers could potentially reduce the production of inflammatory molecules that contribute to the development of these diseases.

In conclusion, MAC-1 is a protein that has been shown to play a critical role in the regulation of various physiological processes that are important for the health and development of the body. As a potential drug target and biomarker, MAC-1 has the potential to revolutionize our understanding of the development and treatment of a wide range of diseases. Further research is needed to fully understand the role of MAC-1 in the regulation of cell behavior and to identify effective drugs or other therapeutic agents that can target MAC-1.

Protein Name: Integrin AlphaMbeta2 (MAC-1) Receptor

The "Integrin alphaMbeta2 (MAC-1) Receptor Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Integrin alphaMbeta2 (MAC-1) Receptor comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets